首页> 外国专利> SUSTAINED-RELEASE COMBINATION PREPARATIONS FOR THE TREATMENT OF DIABETES MELLITUS HAVING ENHANCED COMPLIANCE AND PREPARATION METHOD THEREOF

SUSTAINED-RELEASE COMBINATION PREPARATIONS FOR THE TREATMENT OF DIABETES MELLITUS HAVING ENHANCED COMPLIANCE AND PREPARATION METHOD THEREOF

机译:具有增强顺应性的治疗糖尿病的缓释组合制剂及其制备方法

摘要

The present invention relates to a sustained release combination formulation with improved diabetes for treating diabetes and a method for manufacturing the same and, more specifically, to a sustained release combination formulation for treating diabetes, which is characterized by using a carbomer as a sustained release carrier and a method for manufacturing the same. The sustained release combination formulation comprises: an inner layer containing metformin or a pharmaceutically acceptable salt thereof, a sustained release carrier, and a pharmaceutically acceptable excipient; a drug-free intermediate layer containing water soluble polymers; and an outer layer containing a sulfonylurea-based drug and a release controller. According to the present invention, the sustained release combination formulation for treating diabetes comprising the inner layer containing metformin, the intermediate layer, and the outer layer containing the sulfonylurea-based drug has the same release pattern as amaryl Mex which is an existing combination formulation for treating diabetes, using the carbomer as a sustained release carrier. Also, the sustained release combination formulation does not cause gastrointestinal disorders because the sustained release carrier is almost decomposed within 24 hours and enhances drug compliance through easy administration because the weight of the inner layer is minimized and the size of tablets is reduced. [Reference numerals] (AA) Amaryl Mex;(BB) Example 1
机译:本发明涉及具有改善的糖尿病的用于治疗糖尿病的持续释放组合制剂及其制备方法,更具体地,涉及用于治疗糖尿病的持续释放组合制剂,其特征在于使用卡波姆作为持续释放载体。及其制造方法。缓释组合制剂包括:包含二甲双胍或其药学上可接受的盐的内层,缓释载体和药学上可接受的赋形剂;包含水溶性聚合物的无药物中间层;外层含有磺酰脲类药物和释放控制剂。根据本发明,用于治疗糖尿病的缓释组合制剂包括含有二甲双胍的内层,中间层和含有磺酰脲类药物的外层,其具有与作为用于治疗糖尿病的现有组合制剂的芳基Mex相同的释放模式。卡波姆作为缓释载体治疗糖尿病。同样,持续释放组合制剂不会引起胃肠道疾病,因为持续释放载体在24小时内几乎被分解,并且由于内层的重量被最小化并且减小了片剂的尺寸,因此通过易于给药而增强了药物的顺应性。 [附图标记](AA)芳基Mex;(BB)实施例1

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号